John H. Solomon, MD

Nuclear Medicine Resident, Memorial Sloan Kettering Cancer Center · Completing June 2028

mail@jhs.md LinkedIn ORCID PDF

Training

Nuclear Medicine Residency
2025 – 2028
Memorial Sloan Kettering Cancer Center, Molecular Imaging and Therapy Service, New York, NY
Transitional Year
2024 – 2025
KPC Hemet Global Medical Center, Hemet, CA

Licensure & Certification

License
New York and California, expected 2027
NRC
Authorized User (10 CFR 35.390), expected before residency completion; 200-hour training completed
ABNM
Board eligible 2028

Clinical Software

Myotrace
2025 – present
Cardiac PET reporting and research database, in clinical use.
Clinical reference and calculators
2026 – present
Evidence-graded nuclear medicine clinical reference with interactive calculators.
Radioiodine dosing decision tool
2026 – present
Built on the 2025 ATA risk framework, with evidence-graded recommendations.
Theranostics service tooling
2025 – present
Tumor board intake and worklist; Epic documentation templates for Lu-177, Ra-223 and I-131 therapy.

Research

  1. Roth S, et al. (Solomon J, third author), Murciano-Goroff Y. Efficacy and Tolerability of Selpercatinib in Germline RET-Altered Medullary Thyroid Cancer: A Case Series. In preparation.
  2. Solomon J, Naderi N, Ng QC, Jacobson E. Recognizing Recurrence: History Over Symptoms in Metastatic Melanoma. Cureus. 2025;17(3):e80532.
  3. Samreen I, Solomon J. Unexpected Hemorrhage Post-Paracentesis: Uremic Platelet Dysfunction in an ESRD Patient. Poster, ACP Southern California Chapters. 2024.

Case Presentations

  1. Solomon J, Ravulapalli J, Stolze K, White F. Kyphoplasty Complications: A Rare Case of Cement Embolism. Cureus. 2024.
  2. Solomon J, Porter H, White F. Tuberous Sclerosis Complex. AOCR Case of the Week. 2024.
  3. Solomon J, Schaefer C, Onyi S. Focal Nodular Hyperplasia. AOCR Case of the Week. 2024.

Education

MD
2024
American University of Antigua College of Medicine
BA
2018
University of California, Irvine